Newsbenzinga
Agios Reports Neutral Sickle Cell Data, Decides To Stop Development
· Published
Article summary
Agios Pharmaceuticals stops tebapivat development in sickle cell disease after Phase 2 study fails to prove meaningful differentiation.
An excerpt from the original article.
Comments —
Loading comments…